ArticleCell reports. Medicine2025
Spatial and genomic profiling of residual breast cancer after neoadjuvant chemotherapy unveil divergent fates for each breast cancer subtype.
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Explainable AI-Derived Spatial Pathological Features of Tumor, Necrosis, and Lymphocytes Identify Key Histological Signatures for Residual Cancer Burden Assessment in Breast Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Global research trends and thematic evolution of imaging-guided localization in breast cancer surgery: a bibliometric analysis.Gland surgery · 2026Article
- Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.Med (New York, N.Y.) · 2026Article
- EDNRA Forms a Positive Feedback Loop with the Hippo/YAP Axis to Drive Triple-Negative Breast Cancer Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- 1-Palmitoyl-4-piperidinopiperidine exhibits anticancer effects in murine triple-negative breast cancer EO771 cells associated with STAT3 signaling suppression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Article
- SINTER3D: continuous 3D reconstruction of spatial transcriptomics via implicit neural representations.Genome biology · 2026Article
- PFAS is associated with perineural invasion in triple-negative breast cancer with a potential role for Cathepsin D dysregulation: a multi-omics and experimental study.Clinical and experimental medicine · 2026Article
- MultiSP deciphers tissue structure and multicellular communication from spatial multi-omics data.Cell genomics · 2026Article
- SPP1Cell death & disease · 2026Article
- SpatialFusion: A lightweight multimodal foundation model for pathway-informed spatial niche mapping.bioRxiv : the preprint server for biology · 2026Article
- Proliferative Tumor States and Immunogenic Ecosystems Predict Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.Biomedicines · 2026Article
- SPP1+ Macrophages and the Orchestration of Spatially Organized Immunosuppression in Cancer.Biomedicines · 2026Review
- Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer.Molecular cancer · 2026Article
- A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-Frontiers in oncology · 2026Article
- SNX9 Orchestrates Lung Metastasis via EGFR-ERK Signaling and Actin Cytoskeleton Remodeling in Breast Cancer.Oncology research · 2026Article
- Xiaoyao San alleviates emotional distress - induced TNBC growth through augmenting intratumoral CD8Frontiers in immunology · 2026Article
- Divergent transcriptional programs and constrained metabolic states reveal selective metabolic dependencies in chemoresistant luminal breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2026Article
- Tumor microenvironment response to neoadjuvant therapy in breast cancer: insights from single-cell and spatial omics.Medical oncology (Northwood, London, England) · 2025Review
- Resistance to neoadjuvant chemotherapy in breast cancers: a metabolic perspective.Journal of experimental & clinical cancer research : CR · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Eun Seop SeoDepartment of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Geninus Inc., Seoul 05836, Republic of Korea.
Sabin ParkDepartment of Biomedical Engineering, College of Information-Bio Convergence Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
Eun Yoon ChoDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Jeong Eon LeeDivision of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea.
Hae Hyun JungBiomedical Research Institute, Samsung Medical Center, Seoul 06351, Republic of Korea.
Jiyeon HyeonDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Sepil AnDepartment of Biopharmaceutical Convergence, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea.
Seok Won KimDivision of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Junghoon ShinDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Jin Seok AhnDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Yeon Hee ParkDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Young-Hyuck ImDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Hoon KimDepartment of Biopharmaceutical Convergence, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea; Department of Biohealth Regulatory Science, School of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea; Epigenome Dynamics Control Research Center, Sungkyunkwan University, Suwon-si, Gyeonggi-do 16419, Republic of Korea. Electronic address: wisekh@skku.edu.
Semin LeeDepartment of Biomedical Engineering, College of Information-Bio Convergence Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea. Electronic address: seminlee@unist.ac.kr.
Woong-Yang ParkGeninus Inc., Seoul 05836, Republic of Korea; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Translational Genomics Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Gyeonggi-do 16419, Republic of Korea. Electronic address: woongyang.park@samsung.com.
Ji-Yeon KimDepartment of Digital Health, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Seoul 06355, Republic of Korea; Biomedical Research Institute, Samsung Medical Center, Seoul 06351, Republic of Korea; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. Electronic address: jyeon25@skku.edu.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual cancer burden (RCB) is a strong prognostic marker after neoadjuvant chemotherapy (NAC) in breast cancer (BC), yet some BCs defy their predicted outcomes. Using single-cell spatial transcriptomics and genomic profiling, we investigate mechanisms underlying divergent fates of BCs with high RCB across subtypes. In triple-negative BC (TNBC), CXCL9+ macrophage-CD8
Indexed as
Breast NeoplasmsNeoadjuvant TherapyNeoplasm, ResidualTriple Negative Breast NeoplasmsCD8-Positive T-LymphocytesErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsHumansMacrophagesPrognosisSingle-Cell AnalysisTumor MicroenvironmentErb-b2 Receptor Tyrosine Kinasesbreast cancerextrachromosomal DNAintrinsic subtypeneoadjuvant treatmentresidual cancer burdenspatial transcriptomicswhole-genome sequencing
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.